MITAC-COMPUTING
27.5.2019 04:02:06 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st , Booth # L0631a in Taipei, Taiwan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/
“The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2nd gen Intel® Xeon® Scalable processors and are designed to help enterprises and data center service providers capture, process, and analyze big data faster and at a more powerful rate than ever before.”
2nd Gen Intel Xeon Scalable Processors Empower TYAN HPC and Storage Platforms to Deliver Leading Performance
TYAN’s HPC and storage server platforms are built on the 2nd gen Intel Xeon Scalable processors with accompanying new innovations of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable faster machine learning application execution and accelerated workload processing and service delivery. The new Thunder HX FT83-B7119 is an AI-optimized platform and is ideal for AI training and inference applications. The system supports for up to 3TB of memory and 12 hot-swappable 3.5” drives in a 4U enclosure.
The Thunder SX FA100-B7118 is TYAN’s flagship storage server supporting dual-socket 2nd gen Intel Xeon Scalable processors and 100 3.5” drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. TYAN’s Thunder SX TN76-B7102 is 2U dual-socket 2nd gen Intel Xeon Scalable processor-based storage platform. With support for up to 24 DDR4 DIMM slots and maximum expansion up to 8 standard PCIe slots, the TN76-B7102 can fully address the high memory capacity required by data virtualization and in-memory databases.
For the high-performance storage segment, the Thunder SX GT62H-B7106 is a 1U server platform with support hot-swap all-flash drives. The GT62H-B7106 features dual-socket 2nd gen Intel Xeon Scalable processors, 16 DIMM slots, two low profile PCIe x16 slots, and 10 U.2 NVMe drive bays. This platform offers maximum storage performance and large memory capacity and is ideal for edge server applications.
The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
Intel ® Xeon ® D-2100 and Intel ® Xeon ® E-2100 Processor-based Platforms to Maximize Compute Performance and Efficiency for Cloud and Storage
Powered by the Intel Xeon D-2100 processors, TYAN Thunder SX TE70-B5546 and Thunder SX TE73-B5546 platforms are optimized to deliver rich features of low-power, high-density and high-availability. These two systems are both in 2U dual-node form factor with dual-controller, dual-path redundant design for high availability requirement and support dual-port SAS/NVMe storage functions for today’s high available data-intensive storage environments. TE70-B5546 supports up to 24 2.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2; TE73-B5546 supports up to 12 3.5” dual-port SAS 12Gb/s drive bays and 4 of bays supports dual-port NVMe U.2.
Moreover, taking full advantage of Intel Xeon E-2100 processors, TYAN offers increased reliability, security, performance, and affordability for its entry server lineup. TYAN’s Thunder CX GT24E-B5556 is a 1U single-socket Intel Xeon E-2100 processor-based edge cloud server. With support for up to 4 DDR4 DIMM slots, 3 PCIe slots, and dual 10GBase-T Ethernet ports, the platform is optimized for cost-effective cloud gaming applications. The Thunder CX GX38-B5550 is 1U single-socket Intel Xeon E-2100 processor-based compact sever with shallow chassis and support for 2 3.5” internal SATA drive bays for IoT applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190526005002/en/
Contact:
MiTAC Computing Technology Corporation/ TYAN Business Unit Fenny Chen fenny.chen@tyan.com.tw
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
